Validation of a multiplex immunoassay for serum angiogenic factors as biomarkers for aggressive prostate cancer

Clinica Chimica Acta

Volumn 413, Issue 19-20, 2012, Pages 1506-1511

  Li, Danni ^a   Chiu, Hanching ^a   Gupta, Vinita ^b   Chan, Daniel W ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BIO RAD LABORATORIES   (United States)

Author keywords

Aggressive prostate cancer; Immunoassay; Multiplex; Serum angiogenic factors

Indexed keywords

CD31 ANTIGEN; FIBROBLAST GROWTH FACTOR 2; FOLLISTATIN; GRANULOCYTE COLONY STIMULATING FACTOR; LEPTIN; OSTEOPONTIN; PLATELET DERIVED GROWTH FACTOR AB; PLATELET DERIVED GROWTH FACTOR BB; PROLACTIN; SCATTER FACTOR; SOLUBLE EPIDERMAL GROWTH FACTOR RECEPTOR; SOLUBLE EPIDERMAL GROWTH FACTOR RECEPTOR 2; SOLUBLE INTERLEUKIN 6 RECEPTOR ALPHA; SOLUBLE TRANSMEMBRANE TYROSINE KINASE RECEPTOR 2; SOLUBLE VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 1; SOLUBLE VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2; STEM CELL FACTOR; TUMOR MARKER; UNCLASSIFIED DRUG;

ACCURACY; ANALYTICAL EQUIPMENT; ANALYTICAL PARAMETERS; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CONTROLLED STUDY; GLEASON SCORE; HUMAN; IMMUNOASSAY; LIMIT OF QUANTITATION; LINEARITY; MALE; MULTIPLEX IMMUNOASSAY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; VALIDATION PROCESS;

HUMANS; IMMUNOASSAY; MALE; NEOPLASM GRADING; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; PROSTATIC NEOPLASMS; RECEPTOR, TIE-2; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84863206381     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2012.06.017     Document Type: Article

References (38)

1. Cancer facts & figures 2009 2009, American Cancer Society: American Cancer Society, Atlanta.
2. Cooperberg M.R., Lubeck D.P., Meng M.V., Mehta S.S., Carroll P.R. The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol 2004, 22(11):2141-2149.
3. Weidner N., Carroll P.R., Flax J., Blumenfeld W., Folkman J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 1993, 143(2):401-409.
4. Strohmeyer D., Rossing C., Strauss F., Bauerfeind A., Kaufmann O., Loening S. Tumor angiogenesis is associated with progression after radical prostatectomy in pT2/pT3 prostate cancer. Prostate 2000, 42(1):26-33.
5. Vartanian R.K., Weidner N. Endothelial cell proliferation in prostatic carcinoma and prostatic hyperplasia: correlation with Gleason's score, microvessel density, and epithelial cell proliferation. Lab Invest 1995, 73(6):844-850.
6. Huss W.J., Hanrahan C.F., Barrios R.J., Simons J.W., Greenberg N.M. Angiogenesis and prostate cancer: identification of a molecular progression switch. Cancer Res 2001, 61(6):2736-2743.
7. Ugurel S., Rappl G., Tilgen W., Reinhold U. Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J Clin Oncol 2001, 19(2):577-583.
8. Secord A.A., Darcy K.M., Hutson A., et al. Co-expression of angiogenic markers and associations with prognosis in advanced epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol 2007, 106(1):221-232.
9. Salgia R. Prognostic significance of angiogenesis and angiogenic growth factors in nonsmall cell lung cancer. Cancer 2011, 117(17):3889-3899.
10. Zhang Z., Chan D.W. The road from discovery to clinical diagnostics: lessons learned from the first FDA-cleared in vitro diagnostic multivariate index assay of proteomic biomarkers. Cancer Epidemiol Biomarkers Prev 2010, 19(12):2995-2999.
11. Ellington A.A., Kullo I.J., Bailey K.R., Klee G.G. Antibody-based protein multiplex platforms: technical and operational challenges. Clin Chem 2010, 56(2):186-193.
12. Borre M., Nerstrom B., Overgaard J. Association between immunohistochemical expression of vascular endothelial growth factor (VEGF), VEGF-expressing neuroendocrine-differentiated tumor cells, and outcome in prostate cancer patients subjected to watchful waiting. Clin Cancer Res 2000, 6(5):1882-1890.
13. Kuniyasu H., Troncoso P., Johnston D., et al. Relative expression of type IV collagenase, E-cadherin, and vascular endothelial growth factor/vascular permeability factor in prostatectomy specimens distinguishes organ-confined from pathologically advanced prostate cancers. Clin Cancer Res 2000, 6(6):2295-2308.
14. Strohmeyer D., Rossing C., Bauerfeind A., et al. Vascular endothelial growth factor and its correlation with angiogenesis and p53 expression in prostate cancer. Prostate 2000, 45(3):216-224.
15. Doll J.A., Reiher F.K., Crawford S.E., Pins M.R., Campbell S.C., Bouck N.P. Thrombospondin-1, vascular endothelial growth factor and fibroblast growth factor-2 are key functional regulators of angiogenesis in the prostate. Prostate 2001, 49(4):293-305.
16. Morrissey C., Dowell A., Koreckij T.D., et al. Inhibition of angiopoietin-2 in LuCaP 23.1 prostate cancer tumors decreases tumor growth and viability. Prostate 2010, 70(16):1799-1808.
17. Adler H.L., McCurdy M.A., Kattan M.W., Timme T.L., Scardino P.T., Thompson T.C. Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma. J Urol 1999, 161(1):182-187.
18. Michalaki V., Syrigos K., Charles P., Waxman J. Serum levels of IL-6 and TNF-alpha correlate with clinicopathological features and patient survival in patients with prostate cancer. Br J Cancer 2004, 90(12):2312-2316.
19. Signoretti S., Montironi R., Manola J., et al. Her-2-neu expression and progression toward androgen independence in human prostate cancer. J Natl Cancer Inst 2000, 92(23):1918-1925.
20. Osman I., Scher H.I., Drobnjak M., et al. HER-2/neu (p185neu) protein expression in the natural or treated history of prostate cancer. Clin Cancer Res 2001, 7(9):2643-2647.
21. Shi Y., Brands F.H., Chatterjee S., et al. Her-2/neu expression in prostate cancer: high level of expression associated with exposure to hormone therapy and androgen independent disease. J Urol 2001, 166(4):1514-1519.
22. Morris M.J., Reuter V.E., Kelly W.K., et al. HER-2 profiling and targeting in prostate carcinoma. Cancer 2002, 94(4):980-986.
23. Okegawa T., Kinjo M., Nutahara K., Higashihara E. Pretreatment serum level of HER2/nue as a prognostic factor in metastatic prostate cancer patients about to undergo endocrine therapy. Int J Urol 2006, 13(9):1197-1201.
24. Baron A.T., Cora E.M., Lafky J.M., et al. Soluble epidermal growth factor receptor (sEGFR/sErbB1) as a potential risk, screening, and diagnostic serum biomarker of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 2003, 12(2):103-113.
25. Seetoo D.Q., Crowe P.J., Russell P.J., Yang J.L. Quantitative expression of protein markers of plasminogen activation system in prognosis of colorectal cancer. J Surg Oncol 2003, 82(3):184-193.
26. Kattan M.W., Shariat S.F., Andrews B., et al. The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer. J Clin Oncol 2003, 21(19):3573-3579.
27. van Moorselaar R.J., Voest E.E. Angiogenesis in prostate cancer: its role in disease progression and possible therapeutic approaches. Mol Cell Endocrinol 2002, 197(1-2):239-250.
28. Nakamoto T., Chang C.S., Li A.K., Chodak G.W. Basic fibroblast growth factor in human prostate cancer cells. Cancer Res 1992, 52(3):571-577.
29. Huss W.J., Barrios R.J., Foster B.A., Greenberg N.M. Differential expression of specific FGF ligand and receptor isoforms during angiogenesis associated with prostate cancer progression. Prostate 2003, 54(1):8-16.
30. Humphrey P.A., Zhu X., Zarnegar R., et al. Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. Am J Pathol 1995, 147(2):386-396.
31. Naughton M., Picus J., Zhu X., Catalona W.J., Vollmer R.T., Humphrey P.A. Scatter factor-hepatocyte growth factor elevation in the serum of patients with prostate cancer. J Urol 2001, 165(4):1325-1328.
32. Fudge K., Bostwick D.G., Stearns M.E. Platelet-derived growth factor A and B chains and the alpha and beta receptors in prostatic intraepithelial neoplasia. Prostate 1996, 29(5):282-286.
33. Sitaras N.M., Sariban E., Bravo M., Pantazis P., Antoniades H.N. Constitutive production of platelet-derived growth factor-like proteins by human prostate carcinoma cell lines. Cancer Res 1988, 48(7):1930-1935.
34. Vlahos C.J., Kriauciunas T.D., Gleason P.E., et al. Platelet-derived growth factor induces proliferation of hyperplastic human prostatic stromal cells. J Cell Biochem 1993, 52(4):404-413.
35. Rittling S.R., Chambers A.F. Role of osteopontin in tumour progression. Br J Cancer 2004, 90(10):1877-1881.
36. Amin A., Partin A., Epstein J.I. Gleason score 7 prostate cancer on needle biopsy: relation of primary pattern 3 or 4 to pathological stage and progression after radical prostatectomy. J Urol 2011, 186(4):1286-1290.
37. Tsivian M., Sun L., Mouraviev V., et al. Changes in Gleason score grading and their effect in predicting outcome after radical prostatectomy. Urology 2009, 74(5):1090-1093.
38. Chin K.F., Greenman J., Reusch P., Gardiner E., Marme D., Monson J. Changes in serum soluble VEGFR-1 and Tie-2 receptors in colorectal cancer patients following surgical resections. Anticancer Res 2004, 24(4):2353-2357.